Ventyx Biosciences, Inc.(VTYX)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Pending next ranking run
This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
VTYX Stock Analysis & AI Quality Score
AI stock analysis and institutional research for Ventyx Biosciences, Inc. (VTYX), a Healthcare sector company. VTYX is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q3 2025), Ventyx Biosciences, Inc. reports net income of $-22.8M, free cash flow of $-17.6M. Top institutional holders of VTYX by reported 13-F value include Affinity Asset Advisors,, MORGAN STANLEY, VANGUARD GROUP, based on the most recent SEC filings. VTYX trades on the Nasdaq exchange and files with the SEC under CIK 1851194. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate VTYX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Ventyx Biosciences, Inc. directly from SEC EDGAR.
Net Income
Q3 2025
$-22.8M
Free Cash Flow
Q3 2025
$-17.6M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Net Income
+30.0% YoYOperating Income
+28.6% YoYEPS (Diluted)
+40.3% YoYTotal Assets
-0.4% YoYOp. Cash Flow
+21.4% YoY| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
| Net Income | $-135.1M +30.0% | $-193.0M -78.0% | $-108.4M -29.5% | $-83.7M -197.2% | $-28.2M |
| Operating Income | $-148.4M +28.6% | $-208.0M -83.8% | $-113.1M -68.5% | $-67.1M -852.4% | $-7.0M |
| EPS (Diluted) | $-1.97 +40.3% | $-3.30 -59.4% | $-2.07 +68.9% | $-6.65 | — |
| Total Assets | $276.6M -0.4% | $277.7M -25.2% | $371.4M +27.4% | $291.5M +118872.2% | $245.0K |
| Operating Cash Flow | $-130.9M +21.4% | $-166.5M -68.6% | $-98.8M -155.6% | $-38.6M -523.9% | $-6.2M |
Get alerted when VTYX's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Ventyx Biosciences, Inc. including:
Top Institutional Holders of VTYX
Affinity Asset Advisors, LLC
$58.6M6,484,558 shMORGAN STANLEY
$38.8M4,292,951 shVANGUARD GROUP INC
$35.6M3,943,566 shBlackRock, Inc.
$28.4M3,142,440 shTANG CAPITAL MANAGEMENT LLC
$25.4M2,814,000 shBAKER BROS. ADVISORS LP
$21.2M2,349,280 shBRAIDWELL LP
$17.3M1,920,255 shD. E. Shaw & Co., Inc.
$15.0M1,665,474 shMPM BioImpact LLC
$14.8M1,639,061 shCITADEL ADVISORS LLC
$14.1M1,563,611 sh
| Fund | Value | Shares |
|---|---|---|
| Affinity Asset Advisors, LLC | $58.6M | 6,484,558 |
| MORGAN STANLEY | $38.8M | 4,292,951 |
| VANGUARD GROUP INC | $35.6M | 3,943,566 |
| BlackRock, Inc. | $28.4M | 3,142,440 |
| TANG CAPITAL MANAGEMENT LLC | $25.4M | 2,814,000 |
| BAKER BROS. ADVISORS LP | $21.2M | 2,349,280 |
| BRAIDWELL LP | $17.3M | 1,920,255 |
| D. E. Shaw & Co., Inc. | $15.0M | 1,665,474 |
| MPM BioImpact LLC | $14.8M | 1,639,061 |
| CITADEL ADVISORS LLC | $14.1M | 1,563,611 |
More Healthcare Companies
View all Healthcare →Put VTYX on your watchlist
Track score changes the day Ventyx Biosciences, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is VTYX a good stock to buy?
13F Pro's AI-powered analysis of Ventyx Biosciences, Inc. (VTYX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for VTYX are available on the VTYX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own VTYX?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling VTYX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Ventyx Biosciences, Inc.'s investment landscape.